SZShaohua Zhang

Shaohua Zhang

*This is an algorithmically generated author record based on publicly available information.

Shaohua Zhang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Yang Yuan

    Chinese Peoples Liberat Army Gen Hosp, Dept Breast Oncol, Med Ctr 5, Beijing, Peoples R China

    3 shared publications
  • Zefei Jiang

    Chinese Peoples Liberat Army Gen Hosp, Dept Breast Oncol, Med Ctr 5, Beijing, Peoples R China

    3 shared publications
  • Bing Liu

    State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Senior Department of Hematology, Fifth Medical Center, Medical Innovation Research Department, Chinese PLA General Hospital, Beijing, China

    2 shared publications
  • Haixu Hu

    Department of Medical Oncology, Jefferson University Hospital, 1100 Walnut Street, Philadelphia, PA, 19107, USA

    2 shared publications
  • Jianbin Li

    Chinese Peoples Liberat Army Gen Hosp, Dept Breast Oncol, Med Ctr 5, Beijing, Peoples R China

    2 shared publications
  • Yi Liu

    Senior Department of Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    More than 14 years’ progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report

    by Lina Zhang, Shaohua Zhang, Yang Yuan, Jianbin Li, Feng Li, Cuizhi Geng, Zefei Jiang

    More than 14 years’ progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report Lina Zhang, Shaohua Zhang, Yang Yuan, Jianbin Li, Feng Li, Cuizhi Geng, Zefei Jiang


  • Open Access

    Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study

    by Yang Yuan, Shaohua Zhang, Min Yan, Yongmei Yin, Yuhua Song, Zefei Jiang

    Background: Although endocrine therapy (ET) is the preferred option for hormone receptor-positive HER2-negative metastatic breast cancer (HR+/HER2– MBC), chemotherapy (CT) is still commonly used. The objective of this real-world study was to present the actual choice of first-line treatment for patients with HR+/HER2– MBC and evaluate the consistency with guidelines in China. Methods: Patients with HR+/HER2– MBC between 1996 and September 2018 were identified from of the database of Chinese Society of Clinical Oncology Breast Cancer (CSCO BC). The statistical description was conducted to present the first-line treatment. Factors influencing the prescription of ET or CT were obtained using univariate and multivariate analysis. The consistency of the actual treatment with the guideline of Chinese Society of Clinical Oncology Breast Cancer (CSCO BC guideline) was evaluated. Results: Of 1,877 patients, 662 (35.3%) received ET, and 1,215 (64.7%) received CT. ET proportion was only 25.4% in 1996–2005 and gradually increased to 44.6% in 2016–2018. Aromatase inhibitors (69% of ET) and taxane-based regimens (66% of CT) were the most commonly used ET and CT, respectively. Univariate and multivariate analysis showed that patients with age ≥60, distant relapse-free interval (DRFI) ≥24 months, ER+/PR+, bone metastasis only, or progression on (neo)adjuvant ET were preferably chosen for ET as first-line treatment. Factors associated with preferring CT were de novo stage IV, liver or lung metastasis. 17.2% of patients (322 cases) who had neither visceral metastasis nor progression on (neo)adjuvant ET wrongly received CT instead of ET, which is inconsistent with CSCO BC guideline. More than half of patients receiving CT discontinued their initial treatment due to adverse events and other non-disease progression reasons. Conclusions: Although high proportion of HR+/HER2– MBC patients received CT as first-line treatment in China, it is gratifying to see that the proportion of patients receiving ET has gradually increased. Our study revealed that 17.2% of patients were over-treated according to CSCO BC guideline, which may provide data to promote guideline adherence. The clinical application for ET should be appropriately expanded in first-line treatment, especially for patients without visceral disease and proof of endocrine resistance.


  • Open Access

    Occurrence and distribution of bone metastases in 984 metastatic breast cancer patients

    by Huangchengyu Nie, Yang Yuan, Jianbin Li, Fengrui Xu, Tao Wang, Li Bian, Zefei Jiang, Shaohua Zhang

    Background: An analysis of occurrence and distribution of bone metastases in metastatic breast cancer patients. Methods: This is a retrospective study of 984 metastatic breast cancer patients with bone metastases who were enrolled in our study from January 1, 2010 to December 31, 2019. The main observation indicators were the time of occurrence and the distribution of bone metastases. Results: Computed tomography (CT) was the most common diagnostic method. The main molecular subtype of breast cancer patients with bone metastases was hormone-receptor positive, accounting for 87.2% (858/984) of the study group. Meanwhile, 72.2% (710/984) of the patients were diagnosed with bone metastases within 5 years after the initial diagnosis of breast cancer, and the proportion of patients with bone metastasis found in the 2 to 5 years was the highest. Most bone metastases of breast cancer were multiple osteolytic lesions, the distribution was regular, and axial bones such as chest bones and spine bones were more common than other bones. The most common metastatic site was the ribs (13.4%), followed by the thoracic vertebrae (12.4%), pelvis (12.2%), lumbar vertebrae (12.1%), and sternum (10.5%). Examination of treatment methods revealed that chemotherapy was the most common systemic comprehensive approach, accounting for 89.6% (883/984) of cases, while bone-modifying agents were the most commonly used local treatment for bone metastases, accounting for 86.5% (851/984) of cases. Conclusions: Breast cancer bone metastases have certain clinical features, and understanding the occurrence time and distribution of bone metastases can help guide the clinical diagnosis and treatment of this condition.


  • Open Access

    Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

    by Shaohua Zhang, Lei Li, Tao Wang, Li Bian, Haixu Hu, Chunhong Xu, Bing Liu, Yi Liu, Massimo Cristofanilli, Zefei Jiang

    This study was initiated to investigate the difference in HER2 status between tumor tissue and circulating tumor cells (CTCs), as well as the predictive value of CTC HER2 status for predicting the outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer (MBC) patients. HER2 expression on CTCs was detected using a CellSearch system within 7 days before a new line of anti-HER2 therapy was begun. According to the criterion proposed in our previous report, patients were defined as CTC HER2-positive or -negative. After close follow-up, the correlation between CTC HER2 status and the outcome of the treatment was evaluated by statistical analysis. CTCs were detected in 57.4 % (58/101) of the patients. Notably, 62.1 % (36/58) of these patients had an inconsistent HER2 status between their tissue and CTCs. The discordant rate may correlate with the time interval between histological and CTC HER2 testing and is more likely to occur in the subgroup of patients with an interval of > 1 year than in those with an interval < 1 year (70.7 % vs. 41.2 %, P = 0.043). For PFS, positive HER2 status on CTCs was shown to be a valuable predictor, both in univariate (HR = 0.321, 95%CI, 0.156–0.62, P = 0.0011) and multivariate (HR = 0.383, 95%CI, 0.166–0.831, P = 0.019) Cox regression analysis. Meanwhile, Kaplan-Meier survival curves revealed that the median PFS of CTC HER2-positive patients was significantly longer than CTC HER2-negative ones (8.5 vs. 3.5 months, P < 0.001). HER2 status on CTCs was different from that of tumor tissues and predicted a different outcome of the patients’ anti-HER2 therapy. This difference may be correlated with the time interval between tissue and CTC HER2 testing, indicating the necessity of real-time HER2 analysis for histologically HER2-positive MBC patients.


  • Open Access

    Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

    by Yi Liu, Qian Liu, Tao Wang, Li Bian, Shaohua Zhang, Haixu Hu, Sha Li, Zhiyuan Hu, Shikai Wu, Bing Liu, et al.

    This study was initiated to investigate the prognostic significance of circulating tumor cell (CTC) enumeration and the predictive value of CTC HER2 expression for efficient anti-HER2 therapy in HER2-positive metastatic breast cancer (MBC) patients.